Giampaolo Tortora

Research interests

Publications

• ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer

  New England Journal of Medicine · 2025 · https://doi.org/10.1056/nejmoa2511885

• Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial

  The Lancet Oncology · 2022 · https://doi.org/10.1016/s1470-2045(22)00274-1

• Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

  The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(19)30862-9

• Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1903387

• A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

  Annals of Oncology · 2018 · 10.1093/annonc/mdy263

• Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

  The Lancet · 2017 · https://doi.org/10.1016/s0140-6736(17)32365-6

• Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

  The Lancet · 2017 · https://doi.org/10.1016/s0140-6736(17)32365-6

• Whole-genome landscape of pancreatic neuroendocrine tumours

  Nature · 2017 · https://doi.org/10.1038/nature21063

• Genomic analyses identify molecular subtypes of pancreatic cancer

  Nature · 2016 · https://doi.org/10.1038/nature16965

• Metabolic phenotype of bladder cancer

  Cancer Treatment Reviews · 2016 · https://doi.org/10.1016/j.ctrv.2016.03.005

• Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers

  PLoS ONE · 2015 · https://doi.org/10.1371/journal.pone.0130142

• Whole genomes redefine the mutational landscape of pancreatic cancer

  Nature · 2015 · 10.1038/nature14169

• nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial

  JNCI Journal of the National Cancer Institute · 2015 · https://doi.org/10.1093/jnci/dju413

• Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas

  Nature Genetics · 2013 · https://doi.org/10.1038/ng.2813

• EGFR Antagonists in Cancer Treatment

  New England Journal of Medicine · 2008 · https://doi.org/10.1056/nejmra0707704

• Phase II Trial of Cetuximab in Combination With Fluorouracil, Leucovorin, and Oxaliplatin in the First-Line Treatment of Metastatic Colorectal Cancer

  Journal of Clinical Oncology · 2007 · https://doi.org/10.1200/jco.2007.13.2183

• A Meta-Analysis on the Interaction between HER-2 Expression and Response to Endocrine Treatment in Advanced Breast Cancer

  Clinical Cancer Research · 2005 · https://doi.org/10.1158/1078-0432.ccr-04-2569

• Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy

  Clinical Cancer Research · 2004 · https://doi.org/10.1158/1078-0432.ccr-1100-03

• Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.

  PubMed · 2003

• Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer.

  PubMed · 2002

• ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.

  PubMed · 2002

• Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.

  PubMed · 2001

• A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.

  PubMed · 2001

• Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.

  PubMed · 2000

• Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.

  PubMed · 2000

• Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225.

  PubMed · 1999

Current projects

No projects listed.